Silibinin Inhibits Tumor Growth in a Murine Orthotopic Hepatocarcinoma Model and Activates the TRAIL Apoptotic Signaling Pathway

SOUAD BOUSSEROUEL1, GAETAN BOUR2, HENRIETTE KAUNTZ1, FRANCINE GOSSÉ1, JACQUES MARESCAUX2 and FRANCIS RAUL1

1Laboratory of Nutritional Cancer Prevention, Faculty of Medicine; University of Strasbourg, France; 2Research Institute against Digestive Cancer – European Institute of TeleSurgery, Strasbourg, France

Abstract. Aim: The present study investigated the molecular mechanism of silibinin-induced antitumoral effects in hepatocarcinoma Hep-55.1C cells in vitro and in a hepatocarcinoma model in mice. Materials and Methods: Cell death was analyzed by flow cytometry. The genetic expression of apoptotic and inflammatory biomarkers was assessed by quantitative Reverse Transciptase Polymerase Chain Reaction (qRT-PCR). Orthotopic grafting of Hep-55.1C cells into the liver of C57BL/6J mice was performed, and tumor growth was followed by micro-computed imaging. Results: Silibinin activated the extrinsic apoptotic pathway in Hep55.1C cells, as attested by the up-regulation of TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL Death receptor 5 (DR5) transcripts, and by the activation of caspase-3 and -8. After grafting of Hep-55.1C cells into mouse liver, the oral administration of silibinin at 700 mg/kg body weight for four weeks caused a significant reduction of tumor growth, associated with the down-regulation of inflammatory components [matrix metalloproteinase -7 and -9, (MMP-7, MMP-9), Interleukin-1 beta (IL1β)], the up-regulation of apoptotic mediators (TRAIL, DR5), and caspase-3 activation. Conclusion: Silibinin treatment exerted important anticancerogenic effects, including the activation of TRAIL death receptor apoptotic signaling pathway in Hep-55.1C hepatocarcinoma cells, both in vitro and in hepatocarcinoma grafts in mice.

This article is freely accessible online.

Correspondence to: Dr. Francis Raul, Laboratory of Nutritional Cancer Prevention, IRCAD, 1, Place de l’hôpital, 67091 Strasbourg-Cedex, France. Tel: +33 388119023, Fax: +33388119097. e-mail: francis.raul@ircad.u-strasbg.fr

Key Words: Liver cancer, inflammation, apoptosis, caspases, TRAIL, death receptor.

Hepatocellular carcinoma (HCC) ranks fifth in frequency among common human solid tumors and is the third leading cause of cancer-related death (1). The majority of HCC cases occur in Asia and Sub-Saharan Africa, but in recent years, HCC incidence has been increasing in Western Europe and the United States (2). Liver transplantation and surgical resection are considered as potential curative treatments for HCC. However these procedures are not relevant to HCC patients with concurrent liver cirrhosis, or metastatic spreading (3), and most HCC patients experience liver cancer recurrence after resection (4). Despite the use of several chemotherapeutic drugs in patients with HCC (5, 6), outcomes have not been promising for those with disease at advanced stages due to drug resistance and toxicity (7-9). Therefore, the search for additional drugs exhibiting no systemic toxicity should be widened in order to evaluate their potential growth-inhibitory effects in HCC. In this regard, traditional medicines and several phytochemical agents have been shown to be active towards human HCC cells (10, 11).

The flavonolignan silibinin, the major biologically active compound of milk thistle, has traditionally been used for the treatment of liver diseases in the form of milk thistle extract (12). Studies conducted by our group and others have revealed that in addition to its hepatoprotective effects, silibinin also exhibits strong anticancer efficacy towards various human cancer cell lines and also in several animal cancer models of various origin: prostate, bladder, skin, lung, colon etc. (13-16). We have reported that silibinin induces apoptosis in human colon adenocarcinoma and the derived metastatic cells partly through an activation of the TNF-related apoptosis-inducing ligand (TRAIL) death receptor pathway (16). In addition, we recently showed that intragastric feeding of silibinin to rats developing pre-neoplastic colonic lesions, reduced the number of these lesions by two-fold, inhibited the expression of pro-inflammatory mediators, and activated pro-apoptotic...
processes (17). The present study aimed to determine whether silibinin activated similar mechanisms in Hep-55.1C hepatocarcinoma cells and in an orthotopic murine liver tumor model.

Considering the high lethality of liver cancer, it is necessary to gain further insight in our understanding of the disease and to develop new treatment strategies. For this purpose, several animal models exist, especially mouse models, including orthotopic graft models (18). The orthotopic implantation of HCC cells into the liver mimics better the cell environment, than does subcutaneous implantation. Tumor evolution is however more difficult to study, and on this respect we have reported methods to study tumor evolution non-invasively by micro-computed tomography (CT) follow-up (19, 20). By using syngeneic cells grafted orthotopically in immune-competent mice, the host immune system is active and closely represents the real tumoral microenvironment. Murine HCC cells transplanted into the liver of C57BL/6J mice produce syngeneic orthotopic grafts that histologically reproduce the parental tumors from which they are derived.

Materials and Methods

Cell culture and treatment. Hep55.1C cells (Cell Lines Service, Eppelheim, Germany) were cultured in 75 cm² Falcon flasks in Dulbecco’s modified Eagle’s medium (DMEM) containing 25 mM glucose and supplemented with 10% heat-inactivated (56˚C) horse serum, 100 U/ml penicillin, 100 μg/ml streptomycin and 1% non-essential amino acids (Invitrogen Corp., France). Cells were kept at 37˚C in a humidified atmosphere with 5% CO₂ and were subcultured essential amino acids (Invitrogen Corp., France). Cells were kept at 37˚C in a humidified atmosphere with 5% CO₂ and were subcultured.

Measurement of caspase-3 and caspase-8 activities. Caspase activity was measured by colorimetric assay kits (Sigma-Aldrich) according to the manufacturer's instructions. Briefly, 20 μl of cell lysate or tissue lysate were added to a buffer containing a p-nitroaniline (pNA)-conjugated substrate for caspase-3 (Ac-DEVD-pNA) or -8 (Ac-IETD-pNA) to a total of 100 μl reaction volume. Incubation was carried out at 37˚C. The concentration of the released pNA was calculated from the absorbance values at 405 nm and the calibration curve of defined pNA solutions. Results were adjusted according to the protein content, and activities are expressed as the fold-increase of the caspase activity of the untreated cells. For tissue, activities were expressed as fold-increase of the caspase activity of the tumor tissue over that of the paired adjacent normal liver tissue.

Orthotopic graft of Hep55.1C cells in C57BL/6J mice. Male C57BL/6J mice were purchased from Janvier breeding facilities (St Gen, France) and housed under standard conditions. All animal experiments were performed in accordance with the institutional guidelines of the French Ethical Committee (authorization no. A67-480, French Ministry of Agriculture). For orthotopic tumor graft, 8-week-old C57BL/6J mice were anesthetized by inhalation of isoflurane (Forene, Abbott, Rungis, France). Orthotopic grafting was performed as described previously (20). Briefly, 2×10⁶ Hep-55.1C cells resuspended in 30 μl of PBS (Sigma-Aldrich) were injected into the lateral lobe of the left liver after midline laparotomy. Following hemostasis, the abdomen was closed in two layers. Tumor evolution was followed up by microCT imaging.

MicroCT liver imaging. MicroCT images were obtained on a micro CAT II scanner (Imtek Inc, Knoxville, TN) at 80 kVp X-ray voltage and 500 μA anode current under general gaseous anesthesia with isoflurane (Abbott). Respiratory-gated images were acquired with a resolution of 119 μm leading to a scanned volume of 6.1x6.1x6.1 cm. Based on previous experiments, four hours before the first imaging, animals were injected intraperitoneally with 6 μg Exitron Nano 6000 (Miltenyi, France) liver contrast agent. This nanoparticle-based contrast agent is taken up by macrophages (Küppfer cells) and remains for several weeks in healthy liver, but is not taken up by tumor cells. Hep-55.1C tumors appear as hypodense black areas inside the white contrasted normal liver parenchyma. The presence of a tumor was assessed by microCT scan one week after tumor grafting. Images were analyzed with VR Render software and 3D reconstruction and volume determination was performed with the 3DVP software developed at Research Institute against Digestive Cancer (IRCAD) (21).

Experimental design and treatment. One week after the tumor graft, the mice were randomized into two groups (n=6 per group). The control group received daily gavage (0.3 ml) on 5 days/week for 4 weeks of a vehicle solution (0.5% carboxymethyl cellulose and 0.025% Tween20). The other group received silibinin by gavage at a daily dose of 700 mg/kg body weight on 5 days/week for 4 weeks, in vehicle solution. In both treated and control groups, tumor volumes were recorded by microCT imaging. At the end of the experimental period, after euthanasia, liver tumors were measured with a caliper, isolated, and weighed. The evolution of tumor volume was calculated by normalizing the volume at each time-point from microCT scan images after 3D reconstruction of the tumor with the tumor volume calculated before the first treatment. Tumor volume at autopsy was determined using the semi-ellipsoid volume formula: \( \pi/6 \times \text{length} \times \text{width} \times \text{height} \).
Real-time quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) analysis. Total RNA was isolated from Hep55.1C cells in culture, and from HCC tumor tissue and adjacent normal liver tissue in mice using RNeasy Plus Mini Kit (Qiagen, Austin, TX, USA). A High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA) was used for cDNA synthesis as recommended by the supplier. qRT-PCR was performed by using ABI TaqMan gene expression assays for matrix metalloproteinase 7 and 9 (MMP-7 assay ID: Mm00487724_m1; MMP-9 assay ID: Mm00442991_m1), Interleukin-1 beta (IL1β assay ID: Mm01336189_m1), and Death receptor 5 (DR5 assay ID: Mm00457866_m1), TNF-related apoptosis-inducing ligand (TRAIL assay ID: Mm01283606_m1), and Interferon gamma (IFN-γ assay ID: Mm01168134_m1), according to the manufacturer’s instructions. All samples were run in triplicate in a 25 μl reaction volume. Quantitative real-time RT-PCR was performed using TaqMan Universal PCR Master Mix (Applied Biosystems) and an ABI Prism 7500 Sequence Detection System (Applied Biosystems) in triplicate wells. The data were analyzed using a comparative threshold cycle (CT) method. CT values were calculated using 7500 SDS software (Applied Biosystems). For each sample, expressions of genes were normalized with the mRNA expression of the mouse control gene β-actin (part no. 4352933E) and the fold difference between treated and non-treated Hep-55.1C cells and between tumor tissue and paired adjacent normal liver tissue calculated using the 2^-ΔΔCT method (22).

Statistical analysis. Data are reported as the means±SE. Statistical differences between control and treated groups were evaluated using the Student’s t-test or the Student–Neuman–Keuls multiple comparison test. Differences between groups are considered significant at p<0.05.

Results

Cell death induction by silibinin. After induction of cell death, DNA is degraded, leading to a DNA content lower than 2n per cell. These cells are detected after propidium iodide labeling by flow cytometric analysis in the sub-G0/G1 region (23). We measured the proportion of hypodiploid cells (sub-G0/G1 population) 24, 48 and 72 h after silibinin treatment. Figure 1 shows that the sub-G0/G1 population of Hep-55.1C cells increased progressively with time after silibinin treatment. The percentage of hypodiploid cells rose from 9% (24 h) to 33% (48 h) and to 45% (72 h).

Silibinin activates the extrinsic apoptotic pathway. HCCs show resistance to death receptor-mediated apoptosis because the majority of HCCs exhibit one or more alterations in the TRAIL pathway signaling (24). The TRAIL death receptor DR5 triggers the extrinsic apoptotic pathway when activated (25). Treatment of Hep-55.1C cells with silibinin significantly increased the number of DR5 and TRAIL transcripts compared to untreated cells (Figure 2A and 2B). The enhanced expression of TRAIL and DR5 transcripts is not in itself a proof for the activation of the extrinsic apoptotic pathway, which implies the activation of caspase-8 by DR5. These caspases may then activate the effector caspase-3, leading to cell death. Therefore we assessed the activities of caspase-3 and caspase-8 by measuring the colorimetric reaction product resulting from the cleavage of their respective specific substrates, Ac-DEVD-pNA for caspase-3, and LEHD-pNA for caspase-8. We observed that caspase-3 and caspase-8 were both activated in Hep-55.1C cells treated with silibinin (Figure 3A and 3B).

Silibinin treatment inhibits mice Hep-55.1C liver tumor growth. Based on our data showing the involvement of TRAIL apoptotic pathway in Hep-55.1C cell death triggered by silibinin, we examined the in vivo efficacy of silibinin in orthotopic grafts of Hep-55.1C cells in the liver of C57BL/6J mice. The growth of liver tumors was followed by microCT imaging using a micro CAT II scanner (Figure 4A). The time-dependent growth of HCC tumors was evidenced by an innovative method of 3D reconstruction derived from microCT scans of livers and tumors, allowing the measurement of tumor volume (Figure 4B). The administration of silibinin (700 mg/kg body weight) by oral gavage on 5 days/week for 4 weeks caused a marked time-dependent inhibition in tumor growth in comparison to the

Figure 1. Effects of silibinin on hepatocarcinoma cell death. Hep-55.1C cells were treated with DMSO 0.1% with/without silibinin (150 μg/ml) for 24, 48 or 72 h. At each time point, Hep-55.1C cells were harvested and stained with propidium iodide for the measurement of hypodiploid cells by cell sorting (FACS) histograms after 72 h of treatment. The percentage of silibinin-treated cells in the subG0/G1 region is indicated. In the lower panel, data are the mean value±SE of three separate experiments. *p<0.01 for silibinin treatment versus non-treated control.

![Figure 1](image-url)
tumors of vehicle-treated animals. Longitudinal imaging analysis also provided information on tumor volume change, confirming the efficacy of silibinin treatment (Figure 4B). A three-fold reduction of the relative tumor size was observed in animals receiving silibinin after two weeks of treatment when compared to the untreated group. At autopsy, a three-fold reduction of tumor weight and volume was also recorded (Figure 4C).

Silibinin treatment did not lead to any toxic effects since similar behavior, body weight and diet consumption were observed in control and silibinin-treated mice.

**Inflammatory and apoptotic gene expression changes in liver tumors.** In order to gain more insight into the mechanisms underlying the *in vivo* antitumor efficacy of silibinin, orthotopic tumors were analyzed by real-time quantitative RT-PCR for the differential expression of inflammatory (IL1β), MMP-7 and MMP-9) and innate immunity components (IFN-γ) (Figure 5). As shown in Figure 5A, tumors from silibinin-fed groups exhibited a significant (*p*<0.01) decrease in the expression of both matrix metalloproteinases studied (MMP-7 and MMP-9), when compared to untreated controls. It has been reported that transcription of the MMP genes is positively regulated by cytokines and growth factors such as interleukins (IL1β), suspected to be associated with HCC growth (26-28). Accordingly, we report here a significant up-regulation of both IL1β mRNA (more than 10-fold) in the liver tumor of controls compared to a healthy section of their liver. Silibinin treatment caused a significant (*p*<0.01) reduction of IL1β mRNA, to the level found in the healthy section of the liver (Figure 5B). We also found that the mRNA expression of IFN-γ, a biomarker of the innate immune system, was up-regulated by 25-fold in the liver tumor of silibinin-treated mice compared to the liver tumor of untreated controls (Figure 5B).

Since we observed that silibinin exerted strong apoptotic effects in Hep-55.1C cells through an activation of the TRAIL death receptor apoptotic pathway, we examined the effect of silibinin on the expression of DR5 and TRAIL in liver tumors by quantitative RT-PCR analyses. The present data showed that silibinin treatment significantly (*p*<0.01) up-regulated both DR5 and of TRAIL transcript expressions, (Figure 6A). As shown here in *in vitro* experiments with
Hep-55.1C cells, the activation of the TRAIL death receptor pathway triggers the activation of caspase-3. Accordingly, we found a two-fold increase of caspase-3 activity in tumors of silibinin-treated mice when compared to liver tumors of control mice (Figure 6B).

**Discussion**

Hepatocellular carcinoma (HCC) is one of the most common types of cancer worldwide. HCC is resistant to conventional treatments (chemotherapy and radiotherapy) and this disease is therefore of very poor prognosis, urging for the development of more efficient therapeutic options. One of the key factors for successful use of therapeutic agents is the understanding of the mechanisms regulating drug delivery to the tumor, combined with the ability to provide a clear interpretation of their efficiency. To this aim, several imaging techniques have been developed in live animals, such as magnetic resonance imaging, CT, positron-emission tomography, and whole-body imaging using bioluminescence (29). Here, the growth of liver tumors was followed by micro CT imaging using a micro CAT II scanner. The evaluation of tumor growth was assessed using a 3D software developed at the IRCAD (21). Using this model, in a short-term study we showed that silibinin administered for four weeks, starting one week after orthotopic grafting of Hep-55.1C cells into liver of C57BL/6J mice, significantly reduced tumor growth and size. We hypothesized that these antitumor effects might be correlated to a silibinin-mediated activation of apoptotic cell death in liver tumors. The expression of death receptors DR4 and DR5 belonging to the family of TRAIL receptors are altered in patients with HCC, especially those at advanced stages (30).

In the present study, silibinin treatment induced an important up-regulation of pro-apoptotic TRAIL death receptor DR5 and TRAIL gene expressions. These changes
were associated with activation of caspase-3. These data were in accordance with our in vitro findings showing that silibinin-triggered activation of apoptosis in cultured Hep-55.1C cells was associated with the up-regulation of DR5 transcripts and the activation of caspases 3 and 8. These data show that in both in vivo and in vitro models, silibinin was able to activate the TRAIL death receptor apoptotic pathway.

The drug-resistance of liver tumors might also be related to various cells present in the tumor microenvironment, such as fibroblasts, endothelial cells, and immune cells (31). Fibroblasts, for example, provide growth signals by the secretion of transforming growth factor β, MMPs, and epidermal growth factor (32, 33). MMPs, which are mainly produced by nonmalignant stromal cells, are known to favor tumor growth, invasion, and metastasis (34), and drugs inactivating MMPs have been suggested to be useful in combination therapy with TRAIL (35). Our present data showed that expression of MMP-7 and, to a lesser extent MMP-9, was significantly (*p<0.01) enhanced in the liver tumors and their expression levels were significantly (*p<0.01) reduced by silibinin treatment. Furthermore, we observed that silibinin drastically reduces IL1β expression, which is known to induce the overexpression of MMPs (36). Thus, the reported inhibitory effects of silibinin on liver tumor growth may, also, be related to the down-regulation of these pro-inflammatory factors.

It has been suggested that tumor growth might be efficiently controlled by innate immunity components such as IFN-γ (37). A large number of studies have shown that IFN-γ production by T-cells is essential for tumor elimination (38). Here, we showed that silibinin treatment initiated a significant (*p<0.01) up-regulation in the expression of IFN-γ in liver tumors. Furthermore, we found an inverse correlation between the expression of pro-inflammatory molecules (IL1β, MMP-7, MMP-9), and the expression of IFN-γ.

In conclusion, by using orthotopic syngeneic grafting of Hep-55.1C cells into C57BL/6J mouse liver and monitoring by microCT, we were able to show that the phytochemical
silibinin induced important anticarcinogenic and protective effects on the liver of mice. At a molecular level, these effects were associated with silibinin-induced inhibition of cellular pro-inflammatory factors, including IL1β, MMP-7, and MMP-9 expression, and these changes were associated with the increased expression of the host-defense mediator IFN-γ. We also demonstrated that silibinin-treatment triggered the activation of the TRAIL death receptor apoptotic signaling pathway in both Hep-55.1C hepatocarcinoma cells in vitro and in orthotopic tumor grafts of Hep-55.1C cells in mouse liver.

Acknowledgements

This study was supported by the Conseil Régional d’Alsace (France).

References


Received April 18, 2012
Revised May 25, 2012
Accepted May 28, 2012